Immunicon Corporation announced today an extension
of its Research and Development Agreement with Pfizer, Inc., under which the Company
collaborates with Pfizer to develop new reagents designed to detect certain undisclosed
antigens on circulating tumor cells (CTCs). The collaboration began in February2003
and is now amended to permit the parties to initiate new clinical research studies
by adding new Appendices duly signed by both parties to the Agreement.